Sertraline

Introduction Overview

Generic Name

sertraline

Brand Name

Zoloft

Dosage Form

tablet (25 mg, 50 mg, 100 mg), capsule (150 mg, 200 mg), oral concentrate (20 mg/mL)

Drug Class

Selective serotonin reuptake inhibitors (SSRIs)

Pharmacokinetics

Absorption:
Sertraline is well absorbed after oral administration, with peak plasma concentrations generally reached within 4.5 to 8.4 hours post-dose. Food does not significantly affect the rate or extent of sertraline absorption, allowing flexible dosing with or without meals. The oral bioavailability of sertraline is approximately 44%, attributed to extensive first-pass metabolism in the liver. Due to its delayed peak plasma time, steady-state concentrations are typically achieved after about 7 days of once-daily dosing.

Distribution:
Sertraline exhibits extensive distribution throughout the body with a volume of distribution approximating 20 to 26 L/kg, indicating high tissue binding. It is extensively bound to plasma proteins (about 98%), predominantly albumin and alpha-1-acid glycoprotein, which impacts the fraction of free pharmacologically active drug. Sertraline penetrates the central nervous system efficiently, correlating with its therapeutic effects. It is also able to cross the placental barrier and is excreted into breast milk.

Metabolism:
Metabolic clearance of sertraline occurs primarily via the liver, with cytochrome P450 enzymes, particularly CYP3A4, CYP2B6, CYP2C19, and CYP2D6, contributing to its biotransformation. It undergoes extensive first-pass metabolism resulting in the formation of N-desmethylsertraline, a major plasma metabolite with significantly less pharmacologic activity. Phase I oxidative metabolism is followed by phase II conjugation pathways, including glucuronidation, facilitating elimination. Genetic polymorphisms affecting CYP2C19 can influence sertraline plasma levels.

Elimination:
Sertraline and its metabolites are primarily eliminated via feces (about 65%) with the remainder excreted in urine (approximately 35%). The elimination half-life ranges from 22 to 36 hours, supporting once-daily dosing schedules. The half-life of the active metabolite N-desmethylsertraline is longer, approximately 62 to 104 hours, but it is considered less potent. Clearance may be reduced in patients with hepatic impairment, necessitating dose adjustments. There is no significant renal clearance of unchanged parent sertraline, making it safer in renal dysfunction, but caution is advised with metabolites in severe renal failure.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 25 mg, 50 mg, 100 mg
- Oral capsules: 150 mg, 200 mg
- Oral concentrate solution: 20 mg/mL

Dosages for Adults and Adolescents:
- Major Depressive Disorder (Adults): Initial dose typically 50 mg once daily, with maintenance dosing ranging from 50 to 200 mg once daily.
- Obsessive-Compulsive Disorder (Adults): Starting dose 50 mg daily, maintenance 50–200 mg daily.
- Panic Disorder, Post-Traumatic Stress Disorder, Social Anxiety Disorder (Adults): Initiation at 25 mg once daily for one week, then increase to 50 mg daily, with a maintenance dose range of 50–200 mg daily.
- Premenstrual Dysphoric Disorder (Adults): Continuous regimen – 50 mg daily during menstrual cycle, maintenance up to 150 mg daily; Cyclic regimen – 50 mg daily starting 14 days before menstruation through first full day of menses, maintenance up to 100 mg daily.
- Obsessive-Compulsive Disorder (Pediatrics 6–12 years): Initial dose 25 mg daily, maintenance 25–200 mg daily.
- Obsessive-Compulsive Disorder (Pediatrics 13–17 years): Initial dose 50 mg daily, maintenance 50–200 mg daily.

Specific Patient Populations:
- Pediatric Use: Approved for OCD treatment in children 6 years and older; dosing titrated carefully due to increased susceptibility to adverse effects.
- Geriatric: No specific dose adjustments but caution advised; lower initial dosing may be considered.
- Hepatic Impairment: Dose reduction recommended due to decreased metabolism and clearance.
- Renal Impairment: Although sertraline clearance is not significantly renal, careful monitoring is advised in severe renal dysfunction or failure.
- Patients with Bipolar Disorder: Use with caution due to risk of mania/hypomania activation.

Clinical guidelines emphasize individualized dosing, starting with the lowest effective dose, and gradual titration to reduce side effects and withdrawal symptoms. The oral concentrate must be properly diluted prior to administration using specific beverages, and shaking or improper mixing can affect dosing accuracy. Capsules must not be crushed or chewed to ensure proper pharmacokinetic profile.

Mechanism Of Action

Sertraline functions primarily as a selective serotonin reuptake inhibitor (SSRI), targeting the serotonin transporter (SERT) on presynaptic neurons. By binding selectively to SERT, sertraline blocks the reuptake of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft back into the presynaptic neuron, thereby increasing the availability and duration of serotonin neurotransmission at postsynaptic receptors. This elevation in synaptic serotonin modulates neuronal circuits involved in mood regulation, anxiety, and cognition.

At the molecular level, sertraline exhibits high affinity and selectivity for SERT over other monoamine transporters such as those for norepinephrine and dopamine, reducing off-target effects. This selectivity contributes to its favorable side effect profile compared to older antidepressants. The enhanced serotonergic signaling promotes downstream effects including alterations in receptor density and sensitivity, neuroplasticity, and neurogenesis, processes implicated in the therapeutic effects observed after several weeks of treatment.

Sertraline’s mechanism also influences various central nervous system pathways, modulating the hypothalamic-pituitary-adrenal axis and limbic structures such as the hippocampus and amygdala, which are involved in stress and emotional responses. Research demonstrates that sertraline’s ability to restore the balance of serotonin contributes to alleviation of symptoms in conditions such as depression, anxiety disorders, OCD, PTSD, and PMDD.

Comparatively, sertraline differs from other SSRIs by having a distinct pharmacokinetic profile, slightly different transporter binding kinetics, and also some dopamine transporter affinity at higher doses, which may contribute to its therapeutic efficacy and side effect nuances. Clinical trials and neuroimaging studies support sertraline’s efficacy and safety across mood and anxiety spectrum disorders, reinforcing the central role of serotonergic modulation in these diseases.

Pharmacological Actions

Selective inhibition of serotonin reuptake at the presynaptic neuron increasing synaptic serotonin levels.
Modulation of serotonergic neurotransmission affecting mood, anxiety, and emotional regulation.
Minimal effects on norepinephrine and dopamine reuptake, contributing to a more favorable side effect profile.
Regulation of neuroplasticity and neuronal adaptations in brain regions implicated in depression and anxiety.
Reduction of obsessive-compulsive behaviors through serotonergic pathway modulation.
Attenuation of panic and anxiety responses mediated by limbic system structures.
Normalization of hypothalamic-pituitary-adrenal axis dysregulation observed in stress-related disorders.
Potential dopamine transporter inhibition at higher doses, contributing to mood enhancement.
Anti-anxiety effects important in social anxiety disorder and PTSD management.
Improvement in premenstrual dysphoric disorder symptoms by serotonergic modulation during menstrual cycle.
Minimal anticholinergic, antihistaminic, and adrenergic receptor activity, resulting in lower sedation and cognitive impairment risk.
Influences platelet serotonin uptake, contributing to bleeding risk profile.

Therapeutic Or Clinical Uses

Treatment of major depressive disorder (MDD) in adults.
Management of obsessive-compulsive disorder (OCD) in adults and pediatric patients aged 6 years and older.
Alleviation of panic disorder symptoms with or without agoraphobia.
Treatment of post-traumatic stress disorder (PTSD).
Management of social anxiety disorder (SAD).
Treatment of premenstrual dysphoric disorder (PMDD) using continuous or cyclic regimens.
Reduction of depressive and anxiety symptoms associated with above disorders.
Off-label use in generalized anxiety disorder (GAD) and other anxiety spectrum disorders.
Use in adjunctive therapy for treatment-resistant depression.
Improvement in functional outcomes related to mood and anxiety disorders.
Potential benefit in certain eating disorders characterized by obsessive-compulsive traits.
Use in psychiatric conditions where serotonergic modulation is beneficial.
Treatment option for patients unable to tolerate other classes of antidepressants.
Long-term maintenance therapy to prevent relapse of depressive and anxiety disorders.
Pediatric OCD treatment with careful monitoring and dose titration.

Side Or Adverse Effects

Nausea and gastrointestinal disturbances including diarrhea and indigestion.
Headache and dizziness, commonly during initiation of therapy.
Increased sweating (hyperhidrosis).
Tremor and feeling of shakiness.
Sexual dysfunction including decreased libido, erectile dysfunction, delayed ejaculation, and anorgasmia.
Loss of appetite and potential weight changes including modest long-term weight gain.
Insomnia or somnolence depending on individual response.
Dry mouth and increased salivation in some cases.
Fatigue and weakness reported in some patients.
Serious allergic reactions including rash, hives, and angioedema.
Risk of serotonin syndrome when combined with other serotonergic agents; symptoms include agitation, hallucinations, fever, sweating, muscle stiffness, and coordination loss.
Manic or hypomanic episodes particularly in patients with bipolar disorder.
Hyponatremia particularly in older adults and those on diuretics, manifesting as headache, confusion, and weakness.
Increased risk of bleeding or bruising, especially when combined with NSAIDs, anticoagulants, or platelet inhibitors.
Potential for seizure exacerbation in patients with seizure disorder.
Withdrawal symptoms upon abrupt discontinuation including agitation, sensory disturbances, and flu-like symptoms.

Precautions

Use with caution in patients with a history of bipolar disorder due to risk of activation of mania or hypomania.
Screen for suicidal ideation especially in children, adolescents, and young adults, particularly during initiation or dose changes.
Careful monitoring and dose adjustment advised in hepatic impairment due to metabolism considerations.
Initiate at lower doses in elderly patients and titrate conservatively.
Avoid abrupt discontinuation to prevent withdrawal syndrome; taper dosage gradually.
Use cautiously in patients with seizure disorders as it may lower seizure threshold.
Monitor sodium levels in at-risk populations to prevent hyponatremia.
Assess bleeding risk when used concomitantly with anticoagulants, antiplatelets, or NSAIDs.
Observe for serotonin syndrome when combined with other serotonergic drugs including MAO inhibitors, triptans, and certain herbal supplements.
Consider potential interactions with drugs metabolized by CYP450 enzymes, chiefly CYP2D6 and CYP3A4.
Advise patients regarding possible sexual dysfunction and strategies to manage these effects.
Screen patients for glaucoma, particularly angle-closure glaucoma, before initiation.
Verify pregnancy status and counsel on risks and benefits if pregnant or breastfeeding.
Educate patients about potential drowsiness or impaired ability to perform tasks requiring alertness.
Inform patients about the risk of false-positive results in urine drug screening tests.

Warnings

Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults when starting treatment or changing doses.
Serotonin syndrome risk when sertraline is combined with other serotonergic agents; can be life-threatening without prompt treatment.
Avoid use in combination with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs due to risk of hypertensive crisis or serotonin syndrome.
Potential for increased bleeding risk especially when taken with NSAIDs, aspirin, warfarin, or other anticoagulants.
Activation of mania or hypomania in patients with underlying bipolar disorder.
Use with caution in patients with seizure disorders due to possible lowering of seizure threshold.
Risk of angle-closure glaucoma exacerbation; avoid in untreated narrow-angle glaucoma.
Discontinue gradually to reduce risk of discontinuation syndrome characterized by sensory and neurological symptoms.
Potential neonatal adaptation syndrome when used during pregnancy, including respiratory distress and feeding difficulties.
Monitor for worsening depression symptoms or emergence of suicidal ideation at therapy initiation.
Use caution in patients with long QT syndrome due to reported cases of QT interval prolongation.
Risk of hyponatremia especially in elderly or patients on diuretics.
Avoid concomitant use with pimozide or methylene blue due to serious interactions.
Do not share medication; use only for prescribed indication and patient.
Inform patients to avoid alcohol intake due to additive CNS effects.

Contraindication

Known hypersensitivity or allergy to sertraline or any formulation components.
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation.
Concurrent administration with pimozide due to risk of serious cardiac arrhythmias.
Use of methylene blue injection during treatment because of risk of serotonin syndrome.
Use of disulfiram with sertraline oral concentrate due to formulation excipients causing adverse reactions.
Patients with untreated anatomically narrow-angle glaucoma.
Children under 6 years of age; sertraline is not approved for use in this population.
Known history of severe adverse reaction to selective serotonin reuptake inhibitors.
Patients requiring immediate reversal of serotonergic activity as in cases of hypersensitivity.
Close caution or avoidance in patients with recent or current cerebrovascular event until risks are assessed.
Concurrent use with other serotonergic antidepressants without medical supervision.
Known QT prolongation syndrome or severe cardiac conduction abnormalities.
Patients with uncontrolled epilepsy or recent status epilepticus.
Pregnant patients in whom risks outweigh benefits unless advised by a specialist.
Breastfeeding patients without physician approval or monitoring.

Drug Interactions

Increased risk of serotonin syndrome with concomitant use of other serotonergic drugs such as MAO inhibitors, triptans, tramadol, SSRIs, SNRIs, and St. John's Wort.
Potentiation of bleeding risk when combined with NSAIDs, aspirin, warfarin, or other anticoagulants and antiplatelet agents.
Potential pharmacokinetic interactions with CYP3A4, CYP2B6, CYP2C19, and CYP2D6 metabolized drugs, including certain antipsychotics, antiepileptics, and antivirals.
Concomitant use with pimozide contraindicated due to risk of QT prolongation and cardiac arrhythmias.
Caution when used with methylene blue injection because of risk of severe serotonin syndrome.
Sertraline may increase plasma concentration of drugs metabolized by CYP2D6, such as beta-blockers and tricyclic antidepressants.
Use with disulfiram contraindicated when using sertraline oral concentrate due to excipient incompatibilities.
Additive CNS depressant effects when combined with alcohol, benzodiazepines, opioids, or other CNS-active agents.
Possible reduced efficacy of tamoxifen due to CYP2D6 inhibition by sertraline leading to altered metabolism.
Interactions with stimulant medications or opioid analgesics that can increase risk of adverse serotonergic effects.
Potential alteration in serum levels of digoxin and phenytoin with concurrent administration.
May impact glycemic control in diabetic patients treated with antidiabetic agents.
Avoid concurrent use with triptans without close monitoring due to increased risk of serotonin syndrome.
Herbal supplements such as ginseng, St. John's Wort, and others may synergize serotonergic effects leading to toxicity.
Concomitant use with linezolid (a reversible MAOI) contraindicated due to serotonin syndrome risk.

Preparations Of The Drug

Immediate-release oral tablets: 25 mg, 50 mg, 100 mg for gradual dose escalation and flexible titration.
Oral capsules available in higher doses of 150 mg and 200 mg often reserved for maintenance or treatment-resistant cases.
Oral concentrate (20 mg/mL solution) requiring dilution prior to administration; suitable for patients unable to swallow tablets or requiring precise dosing.
Tablets and capsules coated and formulated for stability and ease of administration without crushing or chewing.
Liquid formulations contain specific excipients including citric acid, sodium citrate, and artificial coloring agents which require caution if allergy exists.
Package includes calibrated dosing devices (syringe or dropper) to ensure accurate dosing for oral concentrate.
Prescription formulations distributed in blister packs, bottles, or unit dose packaging for compliance and safety.
Generic versions available with identical bioequivalence parameters to branded Zoloft preparations.
Manufactured under strict regulatory standards following FDA approvals, with updated labeling reflecting current safety and efficacy data.
Storage recommendations include protection from moisture and light, with room temperature conditions generally applicable.
Available formulations do not include extended-release or delayed-release forms; immediate-release forms require once-daily dosing.
Not formulated for intravenous, intramuscular, or topical administration; strictly oral use only.
Preparation formulations exclude sugar, gluten, or lactose in most cases, catering to specific patient dietary considerations.
Co-packaged with patient information leaflets educating on dosing, side effects, and precautions.
Multiple national and international brands market sertraline in adherence to pharmaceutical standards.